Suggested remit: To appraise the clinical and cost effectiveness of veliparib within its marketing authorisation as maintenance treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 1561

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
06 April 2021 Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
29 July 2020 Following on from advice received from the company the timelines for this appraisal are to be confirmed and further information regarding the scheduling of this appraisal will be available in due course.
27 May 2020 - 24 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual